CJC-1295 (no DAC)

Research Overview

CJC-1295 without DAC, the Modified GRF 1-29 peptide, is a short-acting GHRH analogue and a frequent reference compound wherever physiological GHRH receptor signalling matters. Common research areas:

• Pulsatile growth-hormone release and somatotroph signalling studies
• GHRH receptor sensitivity and tachyphylaxis comparisons against DAC-bound analogues
• Receptor comparisons with GHRP-class secretagogues such as ipamorelin
• Structure and stability work on modified GHRH fragments

The Four Amino-Acid Substitutions

Mod GRF 1-29 differs from native GHRH(1-29), the same active fragment marketed as Sermorelin, at four positions. Each change closes a specific degradation pathway:

1. Position 2: Ala to D-Ala, which resists DPP-4 cleavage at the N-terminus
2. Position 8: Asn to Gln, which prevents asparagine deamidation
3. Position 15: Gly to Ala, which reduces flexibility at a vulnerable site
4. Position 27: Met to Leu, which prevents methionine oxidation

Together these substitutions extend the half-life from roughly 7 minutes for Sermorelin to about 30 minutes for CJC-1295 no DAC, with equivalent or better receptor potency.

Receptor Comparison with Ipamorelin

CJC-1295 no DAC and ipamorelin act on different receptors of the same pituitary somatotroph:

• The GHRH receptor (Gs-coupled), the target of CJC-1295 no DAC, raises cAMP
• The ghrelin receptor GHS-R1a (Gq-coupled), the target of ipamorelin, raises intracellular Ca2+

Milo-Lab lists an Ipamorelin + CJC-1295 blend as a separate product.

Storage

Lyophilised vials: store at -20°C, protected from light.

For research purposes only. Not for human consumption.